AU2019225237B2 - Diagnostic methods using anti-MUC1* antibodies - Google Patents

Diagnostic methods using anti-MUC1* antibodies

Info

Publication number
AU2019225237B2
AU2019225237B2 AU2019225237A AU2019225237A AU2019225237B2 AU 2019225237 B2 AU2019225237 B2 AU 2019225237B2 AU 2019225237 A AU2019225237 A AU 2019225237A AU 2019225237 A AU2019225237 A AU 2019225237A AU 2019225237 B2 AU2019225237 B2 AU 2019225237B2
Authority
AU
Australia
Prior art keywords
antibody
muc1
seq
shows
psmgfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019225237A
Other languages
English (en)
Other versions
AU2019225237A1 (en
AU2019225237A8 (en
Inventor
Cynthia Bamdad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minerva Biotechnologies Corp
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/062569 external-priority patent/WO2019104306A1/en
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Publication of AU2019225237A1 publication Critical patent/AU2019225237A1/en
Publication of AU2019225237A8 publication Critical patent/AU2019225237A8/en
Application granted granted Critical
Publication of AU2019225237B2 publication Critical patent/AU2019225237B2/en
Priority to AU2026201952A priority Critical patent/AU2026201952A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2019225237A 2018-02-26 2019-02-26 Diagnostic methods using anti-MUC1* antibodies Active AU2019225237B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026201952A AU2026201952A1 (en) 2018-02-26 2026-03-16 Diagnostic methods using anti-MUC1* antibodies

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862635378P 2018-02-26 2018-02-26
US62/635,378 2018-02-26
US201862640697P 2018-03-09 2018-03-09
US62/640,697 2018-03-09
AUPCT/US2018/062569 2018-11-27
PCT/US2018/062569 WO2019104306A1 (en) 2017-11-27 2018-11-27 Humanized anti-muc1* antibodies and direct use of cleavage enzyme
US201962791661P 2019-01-11 2019-01-11
US62/791,661 2019-01-11
PCT/US2019/019566 WO2019165421A1 (en) 2018-02-26 2019-02-26 Diagnostic methods using anti-muc1* antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026201952A Division AU2026201952A1 (en) 2018-02-26 2026-03-16 Diagnostic methods using anti-MUC1* antibodies

Publications (3)

Publication Number Publication Date
AU2019225237A1 AU2019225237A1 (en) 2020-09-17
AU2019225237A8 AU2019225237A8 (en) 2020-10-15
AU2019225237B2 true AU2019225237B2 (en) 2025-12-18

Family

ID=67688578

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019225237A Active AU2019225237B2 (en) 2018-02-26 2019-02-26 Diagnostic methods using anti-MUC1* antibodies
AU2026201952A Pending AU2026201952A1 (en) 2018-02-26 2026-03-16 Diagnostic methods using anti-MUC1* antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026201952A Pending AU2026201952A1 (en) 2018-02-26 2026-03-16 Diagnostic methods using anti-MUC1* antibodies

Country Status (8)

Country Link
US (3) US11976132B2 (https=)
EP (1) EP3759145A4 (https=)
JP (2) JP7411559B2 (https=)
CN (1) CN112272677B (https=)
AU (2) AU2019225237B2 (https=)
CA (1) CA3092247A1 (https=)
IL (1) IL276925A (https=)
WO (1) WO2019165421A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
EP3759145A4 (en) * 2018-02-26 2022-03-09 Minerva Biotechnologies Corporation DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES
CN120484122A (zh) * 2019-01-11 2025-08-15 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
BR112022013892A2 (pt) * 2020-01-13 2022-10-04 Truebinding Inc Anticorpos anti-gal3 e métodos de uso
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
WO2021257894A1 (en) * 2020-06-19 2021-12-23 Board Of Regents, The University Of Texas System Anti-bst2 antibodies targeting bst2 long isoform
CA3183682A1 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
GR20200100703A (el) * 2020-11-26 2022-06-08 Icarus Antibodies Ι.Κ.Ε, Μονοκλωνικα αντισωματα εναντι του κορωνοϊου sars-cov-2 και χρησεις αυτων
CN116554317B (zh) * 2022-01-29 2025-02-28 浙江纳米抗体技术中心有限公司 Muc1结合分子及其应用
US20230295276A1 (en) * 2022-03-18 2023-09-21 Novascope Biochips Inc. Antibody for porcine reproductive and respiratory syndrome virus and uses thereof
CN116925216B (zh) * 2022-04-11 2024-09-24 东莞市朋志生物科技有限公司 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒
CN119317447A (zh) 2022-04-12 2025-01-14 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases
WO2025049494A1 (en) 2023-08-29 2025-03-06 Minerva Biotechnologies Corporation Bacterial nme7 orthologs and uses thereof
CN117820483B (zh) * 2024-03-01 2024-05-28 北京纳百生物科技有限公司 一种猫n-端脑利钠肽前体蛋白单克隆抗体、检测试纸条及应用
WO2025255276A1 (en) * 2024-06-04 2025-12-11 Fred Hutchinson Cancer Center Anti-whitlow linker binding domains and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016130726A1 (en) * 2015-02-10 2016-08-18 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5165175B2 (ja) 2000-09-11 2013-03-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１細胞外ドメインおよびそれから得られた癌治療組成物
EP2087007A2 (en) 2006-11-09 2009-08-12 Irm Llc Agonist trkb antibodies and uses thereof
US9249224B2 (en) * 2011-12-22 2016-02-02 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
US10239950B2 (en) 2014-04-28 2019-03-26 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Anti-MUC1 antibody or antigen-binding fragment thereof and uses thereof
EP3759145A4 (en) 2018-02-26 2022-03-09 Minerva Biotechnologies Corporation DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES
CN120484122A (zh) * 2019-01-11 2025-08-15 米纳瓦生物技术公司 抗可变muc1*抗体及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016130726A1 (en) * 2015-02-10 2016-08-18 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies

Also Published As

Publication number Publication date
WO2019165421A1 (en) 2019-08-29
US12351646B2 (en) 2025-07-08
JP2024045120A (ja) 2024-04-02
IL276925A (en) 2020-10-29
US20240352149A1 (en) 2024-10-24
AU2026201952A1 (en) 2026-04-02
JP2021514973A (ja) 2021-06-17
US20200407462A1 (en) 2020-12-31
AU2019225237A1 (en) 2020-09-17
EP3759145A1 (en) 2021-01-06
US11976132B2 (en) 2024-05-07
JP7705442B2 (ja) 2025-07-09
EP3759145A4 (en) 2022-03-09
CN112272677B (zh) 2024-10-29
JP7411559B2 (ja) 2024-01-11
CN112272677A (zh) 2021-01-26
CA3092247A1 (en) 2019-08-29
AU2019225237A8 (en) 2020-10-15
US20250066505A1 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
AU2019225237B2 (en) Diagnostic methods using anti-MUC1* antibodies
EP3677910B1 (en) Diagnosing pancreatic cancer using methionyl-trna synthetase and ck19
JP6977105B2 (ja) Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用
WO2022154037A1 (ja) がんの予後バイオマーカー
RU2706959C2 (ru) Антитело к igf-1r и его применение для диагностики рака
US20230340147A1 (en) Antibodies specific for alpha-1,6-core-fucosylated psa and fucosylated fragments thereof
WO2023100153A1 (en) Use of anti-cd70 antibodies for identifying subjects susceptible for treatment with nk cell-based anti-cd70 therapy
HK1262633B (zh) 用於评估癌症发生的风险的组合物和方法
OA18453A (en) IGF-1R antibody and its use for the diagnosis of cancer

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 34 , NO 37 , PAGE(S) 5245 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME MINERVA BIOTECHNOLOGIES CORPORATION., APPLICATION NO. 2019225237, UNDER INID (54) CORRECT THE TITLE TO READ DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES

FGA Letters patent sealed or granted (standard patent)